KraneShares Electric Vehicles and Future Mobility vs uniQure N.V. Ordinary Shares — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $26.6 (market cap $70.90M), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 20.5× KraneShares Electric Vehicles and Future Mobility's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 48 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| KARS | QURE | |
|---|---|---|
Market Cap | $70.90M | $1.45B |
Volume | 2,312 | 3,323,243 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $70.59 |
52-Week Low | $26.72 | $9.03 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $707.46M |
Signals from Pluang's Aura AI — not financial advice
KARS stock trades at $27.18, down 0.88% on the day with a bearish technical signal. The stock faces resistance at $29 and support at $28, with moving averages indicating selling pressure while oscillators remain neutral. Recent news highlights challenges in the US electric vehicle market, which may impact automotive sector performance.
The outlook remains cautious given technical weakness and sector headwinds. Investment opportunity depends on company-specific fundamentals currently unavailable, while risks include EV market softness and regulatory uncertainty surrounding Chinese competition in the automotive industry.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →